• OPEN AN ACCOUNT
Indian Indices
Sensex
83,576.24 -604.72
( -0.72%)
Global Indices
Nasdaq
49,520.87 233.75
(0.47%)
Dow Jones
6,986.78 44.32
(0.64%)
Hang Seng
51,918.01 800.75
(1.57%)
Nikkei 225
10,123.15 78.46
(0.78%)
Forex
USD-INR
89.91 -0.02
(-0.02%)
EUR-INR
104.90 -0.20
(-0.19%)
GBP-INR
120.86 -0.43
(-0.35%)
JPY-INR
0.57 0.00
(-0.15%)

EQUITY - MARKET SCREENER

Infollion Research Services Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
78698
INE0NNZ01013
55.6873548
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
INFOLLION
33.78
369.79
EPS(TTM)
Face Value()
Div & Yield %
11.29
10
0
 

Concord Drugs gains on securing Rs 15-cr order
Dec 30,2025
The project involves supplying various government healthcare agencies, including TNMSC (six purchase orders), DGHS via Government Medical Stores Depots, TNMSC under the Mudhalvar Marundhagam Scheme (32 purchase orders), TGMSIDC, and other entities, with execution scheduled over the next 45 to 60 days.

Concord Drugs is engaged in the manufacture of licensed pharmaceutical products based on approved formulations.

The company’s consolidated net profit surged 375% to Rs 0.19 crore on a 16.8% drop in revenue to Rs 10.28 crore in Q2 FY26 over Q2 FY25.